Sign In / Join

favorite Donate

close

person Sign In / Create Account

Peripheral T-Cell Lymphoma Podcasts

HealthTree Podcasts for Peripheral T-Cell Lymphoma features in-depth interviews with Peripheral T-Cell Lymphoma experts. These programs are a deep dive into a single topic about Peripheral T-Cell Lymphoma and help patients understand the latest in research and ongoing clinical trials.

Upcoming Show

Episode 4: Clinical Trials: Myths, Facts, and What Patients Need to Know

May 12, 2025 / 12:00PM EDT

Episode 4: Clinical Trials: Myths, Facts, and What Patients Need to Know image

Episode 4: Clinical Trials: Myths, Facts, and What Patients Need to Know image

Upcoming Show

May 12, 2025 / 12:00PM EDT

Episode 4: Clinical Trials: Myths, Facts, and What Patients Need to Know

Episode 3: Young Adult AML: Understanding the Gaps & Closing Them

May 05, 2025 / 12:00PM EDT

Episode 3: Young Adult AML: Understanding the Gaps & Closing Them

play_circle_filled Listen to Episode

Episode 2: Fighting AML in Young Patients: New Research & the Future of CAR-T

Apr 28, 2025 / 12:00PM EDT

Episode 2: Fighting AML in Young Patients: New Research & the Future of CAR-T

play_circle_filled Listen to Episode

Episode 1: When Should Treatment Start? What AML Patients Need to Know

Apr 21, 2025 / 12:00PM EDT

Episode 1: When Should Treatment Start? What AML Patients Need to Know

play_circle_filled Listen to Episode

Menin Inhibitors 101 with Dr. Joshua Zeidner image

Menin Inhibitors 101 with Dr. Joshua Zeidner

Jul 09, 2024

Jul 09, 2024 / 05:00PM EDT

Adult AML Chapter

Reducing Relapse Risk After Transplant Using Jakafi With Gabriela Hobbs, MD, Massachusetts General Hospital image

Reducing Relapse Risk After Transplant Using Jakafi With Gabriela Hobbs, MD, Massachusetts General Hospital

Oct 05, 2022

Oct 05, 2022 / 01:30PM EDT

HealthTree Podcast for AML

Expanding the Use of Ivosidenib (Tibsovo) In Newly Approved Combination For IDH1-Mutated AML with Eytan Stein, MD, Memorial Sloan Kettering image

Expanding the Use of Ivosidenib (Tibsovo) In Newly Approved Combination For IDH1-Mutated AML with Eytan Stein, MD, Memorial Sloan Kettering

Aug 24, 2022

Aug 24, 2022 / 11:00AM EDT

HealthTree Podcast for AML

Digging Deeper Into the TP53 Mutation in AML with Rory Shallis, MD, Yale New Haven Hospital image

Digging Deeper Into the TP53 Mutation in AML with Rory Shallis, MD, Yale New Haven Hospital

Jul 14, 2022

Jul 14, 2022 / 11:00AM EDT

HealthTree Podcast for AML

Weighing FLT3 Inhibitor Options with Dr. Jane Liesveld, University of Rochester image

Weighing FLT3 Inhibitor Options with Dr. Jane Liesveld, University of Rochester

Jun 29, 2022

Jun 29, 2022 / 02:00PM EDT

HealthTree Podcast for AML

Attacking AML Cells with a New Immunotherapy Infusion with Kendra Sweet, MD, Moffitt Cancer Center image

Attacking AML Cells with a New Immunotherapy Infusion with Kendra Sweet, MD, Moffitt Cancer Center

Jun 09, 2022

Jun 09, 2022 / 01:00PM EDT

HealthTree Podcast for AML

Killing AML Cells with Magrolimab, a New Immunotherapy Option, with Dr. Joseph Jurcic image

Killing AML Cells with Magrolimab, a New Immunotherapy Option, with Dr. Joseph Jurcic

May 26, 2022

May 26, 2022 / 11:00AM EDT

HealthTree Podcast for AML

Targeting FLT3 Positive AML with New & Improved Therapies with Dr. Margaret Kasner image

Targeting FLT3 Positive AML with New & Improved Therapies with Dr. Margaret Kasner

Feb 07, 2022

Feb 07, 2022 / 01:00PM EST

HealthTree Podcast for AML

AML Progress in 2021 and a Look to the Future with Dr. Eytan Stein image

AML Progress in 2021 and a Look to the Future with Dr. Eytan Stein

Feb 02, 2022

Feb 02, 2022 / 12:00PM EST

HealthTree Podcast for AML

The Latest in AML Treatment Advances: Where We Are and Where We're Going with James Blachly, MD, Ohio State University image

The Latest in AML Treatment Advances: Where We Are and Where We're Going with James Blachly, MD, Ohio State University

Oct 25, 2021

Oct 25, 2021 / 02:00PM CDT

HealthTree Podcast for AML

Harnessing the Immune System in Relapsed/Refractory AML with Dr. John Reagan, Rhode Island Hospital image

Harnessing the Immune System in Relapsed/Refractory AML with Dr. John Reagan, Rhode Island Hospital

Sep 30, 2021

Sep 30, 2021 / 12:00PM CDT

HealthTree Podcast for AML

Progress Toward an All Oral Treatment for Newly Diagnosed Older Adults with AML with Gabriel Mannis, MD image

Progress Toward an All Oral Treatment for Newly Diagnosed Older Adults with AML with Gabriel Mannis, MD

Sep 13, 2021

Sep 13, 2021 / 03:00PM CDT

HealthTree Podcast for AML

Menin Inhibitors 101 with Dr. Joshua Zeidner

Jul. 09, 2024

Menin Inhibitors 101 with Dr. Joshua Zeidner

play_circle_filled Listen to Episode

Reducing Relapse Risk After Transplant Using Jakafi With Gabriela Hobbs, MD, Massachusetts General Hospital

Oct. 05, 2022

Reducing Relapse Risk After Transplant Using Jakafi With Gabriela Hobbs, MD, Massachusetts General Hospital

play_circle_filled Listen to Episode

Expanding the Use of Ivosidenib (Tibsovo) In Newly Approved Combination For IDH1-Mutated AML with Eytan Stein, MD, Memorial Sloan Kettering

Aug. 24, 2022

Expanding the Use of Ivosidenib (Tibsovo) In Newly Approved Combination For IDH1-Mutated AML with Eytan Stein, MD, Memorial Sloan Kettering

play_circle_filled Listen to Episode

Digging Deeper Into the TP53 Mutation in AML with Rory Shallis, MD, Yale New Haven Hospital

Jul. 14, 2022

Digging Deeper Into the TP53 Mutation in AML with Rory Shallis, MD, Yale New Haven Hospital

play_circle_filled Listen to Episode

Weighing FLT3 Inhibitor Options with Dr. Jane Liesveld, University of Rochester

Jun. 29, 2022

Weighing FLT3 Inhibitor Options with Dr. Jane Liesveld, University of Rochester

play_circle_filled Listen to Episode

Attacking AML Cells with a New Immunotherapy Infusion with Kendra Sweet, MD, Moffitt Cancer Center

Jun. 09, 2022

Attacking AML Cells with a New Immunotherapy Infusion with Kendra Sweet, MD, Moffitt Cancer Center

play_circle_filled Listen to Episode

Killing AML Cells with Magrolimab, a New Immunotherapy Option, with Dr. Joseph Jurcic

May. 26, 2022

Killing AML Cells with Magrolimab, a New Immunotherapy Option, with Dr. Joseph Jurcic

play_circle_filled Listen to Episode

Targeting FLT3 Positive AML with New & Improved Therapies with Dr. Margaret Kasner

Feb. 07, 2022

Targeting FLT3 Positive AML with New & Improved Therapies with Dr. Margaret Kasner

play_circle_filled Listen to Episode

AML Progress in 2021 and a Look to the Future with Dr. Eytan Stein

Feb. 02, 2022

AML Progress in 2021 and a Look to the Future with Dr. Eytan Stein

play_circle_filled Listen to Episode

The Latest in AML Treatment Advances: Where We Are and Where We're Going with James Blachly, MD, Ohio State University

Oct. 25, 2021

The Latest in AML Treatment Advances: Where We Are and Where We're Going with James Blachly, MD, Ohio State University

play_circle_filled Listen to Episode

podcasts $Harnessing the Immune System in Relapsed/Refractory AML with Dr. John Reagan, Rhode Island Hospital$

Sep. 30, 2021

Harnessing the Immune System in Relapsed/Refractory AML with Dr. John Reagan, Rhode Island Hospital

play_circle_filled Listen to Episode

Progress Toward an All Oral Treatment for Newly Diagnosed Older Adults with AML with Gabriel Mannis, MD

Sep. 13, 2021

Progress Toward an All Oral Treatment for Newly Diagnosed Older Adults with AML with Gabriel Mannis, MD

play_circle_filled Listen to Episode

Trending Articles

Menin Inhibitors: A New Treatment Option for Acute Leukemia Patients

What Works Better for AML: Intensive Chemotherapy or Venetoclax/HMAs?

Understanding the Timing of Treatment in Acute Myeloid Leukemia (AML)

Understanding Cancer Cachexia and Its Impact on AML Survival

Which CAR-T is the Best for You? Comparing Cilta-cel and Ide-cel

Upcoming Events

Episode 4: Clinical Trials: Myths, Facts, and What Patients Need to Know

Episode 4: Clinical Trials: Myths, Facts, and What Patients Need to Know

May 12 / 12:00 EDT

Pilates for Wellness: A Class for AML & MDS Patients

Pilates for Wellness: A Class for AML & MDS Patients

May 13 / 14:30 EDT

Understanding FLT3 in AML: What It Means and How It’s Treated

Understanding FLT3 in AML: What It Means and How It’s Treated

May 15 / 15:00 EDT

All HealthTree resources available anywhere, anytime

Download our App

Download iOS App

Download Android App

iphone app mockup

Download our App

Download iOS App

Download Android App

Charity Navigator

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Copyright © 2025 HealthTree Foundation. All rights reserved.

Tax ID 45-5354811